

# Daniel Stadlbauer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/857726/publications.pdf>

Version: 2024-02-01

35  
papers

6,697  
citations

279798

23  
h-index

361022

35  
g-index

43  
all docs

43  
docs citations

43  
times ranked

14146  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 during pregnancy and associated outcomes: Results from an ongoing prospective cohort. Paediatric and Perinatal Epidemiology, 2022, 36, 466-475.	1.7	17
2	Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nature Communications, 2022, 13, .	12.8	19
3	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	30.7	204
4	Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. Nature, 2021, 590, 146-150.	27.8	128
5	Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines, 2021, 9, 40.	4.4	14
6	A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. Journal of Clinical Investigation, 2021, 131, .	8.2	35
7	AS03-adjuvanted H7N9 inactivated split virion vaccines induce cross-reactive and protective responses in ferrets. Npj Vaccines, 2021, 6, 40.	6.0	8
8	SARS-CoV-2 Infection Risk Among Active Duty Military Members Deployed to a Field Hospital â€” New York City, April 2020. Morbidity and Mortality Weekly Report, 2021, 70, 308-311.	15.1	18
9	SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe, The, 2021, 2, e283-e284.	7.3	344
10	Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. New England Journal of Medicine, 2021, 384, 1372-1374.	27.0	659
11	Differential T-Cell Reactivity to Endemic Coronaviruses and SARS-CoV-2 in Community and Health Care Workers. Journal of Infectious Diseases, 2021, 224, 70-80.	4.0	65
12	Immunological imprinting of the antibody response in COVID-19 patients. Nature Communications, 2021, 12, 3781.	12.8	149
13	SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study. Lancet Respiratory Medicine, the, 2021, 9, 712-720.	10.7	136
14	Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial. Npj Vaccines, 2021, 6, 89.	6.0	15
15	Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. Heliyon, 2021, 7, e08444.	3.2	8
16	Pre-existing Antineuraminidase Antibodies Are Associated With Shortened Duration of Influenza A(H1N1)pdm Virus Shedding and Illness in Naturally Infected Adults. Clinical Infectious Diseases, 2020, 70, 2290-2297.	5.8	56
17	Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17957-17964.	7.1	57
18	Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses. Cell Host and Microbe, 2020, 28, 614-627.e6.	11.0	76

#	ARTICLE	IF	CITATIONS
19	<scp>Antiâ€SARSâ€CoV</scp>â€2 spike antibodies are stable in convalescent plasma when stored at 4Â° Celsius for at least 6â€weeks. <i>Transfusion</i> , 2020, 60, 2457-2459.	1.6	17
20	Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. <i>Science</i> , 2020, 370, 1227-1230.	12.6	1,035
21	Convalescent plasma treatment of severe COVID-19: a propensity scoreâ€matched control study. <i>Nature Medicine</i> , 2020, 26, 1708-1713.	30.7	405
22	A serological assay to detect SARS-CoV-2 seroconversion in humans. <i>Nature Medicine</i> , 2020, 26, 1033-1036.	30.7	1,678
23	SARSâ€CoVâ€2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. <i>Current Protocols in Microbiology</i> , 2020, 57, e100.	6.5	670
24	Antibody responses to influenza A(H1N1)pdm infection. <i>Vaccine</i> , 2020, 38, 4221-4225.	3.8	4
25	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. <i>Frontiers in Immunology</i> , 2019, 10, 2005.	4.8	48
26	Characterization of swine-origin H1N1 canine influenza viruses. <i>Emerging Microbes and Infections</i> , 2019, 8, 1017-1026.	6.5	13
27	Broadly protective human antibodies that target the active site of influenza virus neuraminidase. <i>Science</i> , 2019, 366, 499-504.	12.6	162
28	Novel correlates of protection against pandemic H1N1 influenza A virus infection. <i>Nature Medicine</i> , 2019, 25, 962-967.	30.7	138
29	Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs. <i>MBio</i> , 2019, 10, .	4.1	51
30	Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. <i>Frontiers in Immunology</i> , 2019, 10, 756.	4.8	48
31	Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts. <i>Npj Vaccines</i> , 2019, 4, 51.	6.0	18
32	Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice. <i>ImmunoHorizons</i> , 2019, 3, 133-148.	1.8	33
33	Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	6.5	24
34	Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans. <i>MSphere</i> , 2017, 2, .	2.9	36
35	Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?. <i>Frontiers of Medicine</i> , 2017, 11, 471-479.	3.4	9